When will Gilteritinib enter medical insurance?

As an original targeted drug developed by Astellas, Gilitinib/Gilteritinib has been approved overseas for the treatment of FLT3 mutation-positive relapsed or refractory acute myeloid leukemia (AML) and has shown significant clinical efficacy. However, in China, although giritinib has completed marketing approval, it has not yet been included in the national medical insurance directory, which also means that patients need to pay for the drug in full out of pocket. The common market sales specification is 40mg/21 tablets/2 plates, and the economic burden of long-term medication cannot be ignored.

In the process of domestic medical insurance access, negotiations for tumor-targeted drugs often need to combine multiple factors such as clinical value, patient demand, and drug price. Because of its innovative nature and irreplaceability in specific groups of people, giritinib has always been considered to be expected to be included in the medical insurance catalog. In recent years, the country has continued to advance its medical insurance negotiations for anti-cancer drugs, and the prices of many imported original drugs have been significantly reduced through negotiations, thus greatly improving patient accessibility. Therefore, judging from policy trends, the possibility of giritinib being included in medical insurance in the future is still high.

Before medical insurance covers them, some patients will choose overseas drug purchase channels or seek assistance programs to relieve financial pressure. However, these methods have certain risks in terms of quality supervision and medication safety, so purchasing through formal channels is still the first choice. While patients and their families are concerned about the efficacy of drugs, they also hope that medical insurance policies will benefit them as soon as possible and reduce the economic burden of long-term treatment.

As the demand for personalized precision drugs in the field of AML treatment continues to increase, the entry of geritinib into the medical insurance directory will not only help more patients afford targeted treatments, but will also further promote the popularization of genetic testing and targeted drugs. The dynamic adjustment of medical insurance policies is becoming an important guarantee for promoting inclusive coverage of innovative drugs, and whether giritinib can be included in medical insurance will be directly related to the treatment accessibility and survival hope of AML patients.

Reference materials:https://www.xospata.com/